Cutler Group LP Atossa Therapeutics, Inc. Transaction History

Cutler Group LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	SELL	$0.59 - $0.91 $11,598 - $17,889	-19,659 Reduced 97.16%	574 $0
Q4 2022 Feb 07, 2023	BUY	$0.5 - $1.01 $2,949 - $5,956	5,898 Added 41.14%	20,233 $10,000
Q3 2022 Oct 25, 2022	BUY	$0.82 - $1.14 $10,278 - $14,289	12,535 Added 696.39%	14,335 $11,000
Q2 2022 Aug 04, 2022	SELL	$0.85 - $1.28 $19,031 - $28,659	-22,390 Reduced 92.56%	1,800 $1,000
Q4 2021 Jan 18, 2022	SELL	$1.6 - $3.27 $76,782 - $156,924	-47,989 Reduced 66.49%	24,190 $38,000
Q2 2021 Jul 19, 2021	BUY	$1.52 - $8.62 $42,789 - $242,661	28,151 Added 63.94%	72,179 $456,000
Q1 2021 Apr 26, 2021	BUY	$0.92 - $4.33 $39,677 - $186,744	43,128 Added 4792.0%	44,028 $92,000
Q4 2020 Jan 21, 2021	BUY	$0.85 - $2.43 $680 - $1,944	800 Added 800.0%	900 $0
Q2 2020 Jul 22, 2020	BUY	$1.04 - $4.05 $104 - $405	100 New	100 $0

26.5M

466K

91.8K

Ticker ATOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,624,000
Market Cap $162M
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.